Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 3/20 | 0.35 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826846 | 0.89 | TMPRSS2 (0.32) | TMPRSS2PIK3CD | |
| SCHEMBL25825428 | 0.84 | PIK3CD (0.31) | ACVRL1PIK3CD | |
| SCHEMBL25826842 | 0.82 | TMPRSS2 (0.42) | TMPRSS2 | |
| SCHEMBL23959862 | 0.81 | TMPRSS2 (0.47) | ACVRL1TMPRSS2 | |
| SCHEMBL25827054 | 0.81 | POLRMT (0.36) | — | |
| SCHEMBL23959995 | 0.76 | TMPRSS2 (0.40) | ACVRL1TMPRSS2 | |
| SCHEMBL24606241 | 0.75 | TMPRSS2 (0.39) | ACVRL1TMPRSS2PIK3CDTNK2 | |
| SCHEMBL23960113 | 0.75 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL24606249 | 0.75 | TMPRSS2 (0.38) | ACVRL1TMPRSS2PIK3CDTNK2 | |
| SCHEMBL24606253 | 0.74 | TMPRSS2 (0.37) | ACVRL1TMPRSS2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | ACVRL1 712/4885TMPRSS2 145/4885EGLN2 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.